Price List - Omlyclo - Atopy - NA.xlsx
XLSX spreadsheet 44 KB Posted
- Solicitation number
- HT9402-26-Q-9403
- Issued by
-
Defense Health Agency
About this file
This is a pricing template and submission form for pharmaceutical agents being considered for inclusion in the Department of War (DoW) Uniform Formulary (UF) for the Military Health System. The document is specifically formatted for Omlyclo, a newly approved drug in the Atopy therapeutic class, with a P&T Committee meeting scheduled for November 4-5, 2026. Quotes are due by September 24, 2026. The template includes multiple appendices structured for different procurement vehicles: Blanket Purchase Agreement (BPA) pricing for Military Treatment Facilities and Mail Order scenarios, and Additional Discount Program (ADP) pricing for both non-FAMP discounts and Wholesale Acquisition Cost (WAC) discounts for TRICARE retail refunds. For BPA submissions, manufacturers must provide price per unit across different formulary categories (Uniform Formulary and Non-Formulary). For ADP submissions, manufacturers must provide non-FAMP pricing, additional refund percentages, or WAC discounts depending on the pricing approach selected, with tier designations (Tier 2 and Tier 3) specified in the formulary scenarios.
Manufacturers submitting quotes must include the Quote Review Checklist and fully executed signature pages along with all pricing information. The price per unit of measure must remain consistent across all available package sizes (e.g., 30s, 100s, 1000s) within a given dispensing venue. The P&T Committee may designate agents with step therapy requirements, recommend preferential status for non-generic agents by classifying them as Tier 1 (generic cost-sharing), or completely exclude agents from the TRICARE pharmacy benefit program. Prior Authorization may apply with steps including any or all generic agents for new and current users.
View the file
Other files
| File | Type | Posted |
|---|---|---|
| Formulary Placement of FDA NADs.pdf | ||
| RFQ HT9402-26-Q-9403 NAD.pdf | ||
| Price List - Furoscix ReadyFlow - Diuretics - NA.xlsx | XLSX spreadsheet | |
| Price List - Jideytro - Lung Cancer - NA.xlsx | XLSX spreadsheet | |
| Price List - Zenbexus - Multiple Myeloma - NA.xlsx | XLSX spreadsheet | |
| Price List - Gywn Lo - Contraceptive Agents - Misc.xlsx | XLSX spreadsheet | |
| Price Appendix FAQ NAD.pdf | ||
| Price List - RizaFilm - Migraine Agents - NA.xlsx | XLSX spreadsheet |
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
BPA
| UF BPA NDC Price List for the November 2026 DoW P&T Meeting | |||
| DoW Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | November 4-5, 2026 |
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 |
| Formulary Notes | |||
| Class Note(s): Prior Authorization (PA) may apply and allows for a step that includes any/all generic agents for all new and current users. Agents where no brand currently exists may be considered for tier designation. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend as Completely Excluded from the TRICARE pharmacy benefit program. |
Step Therapy Addendum: Agents with RFQ not submitted or selected may be designated non-step preferred (after-step).
Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.
The price per unit of measure for a given dosage form and strength (each, gram, mL, etc.) of the pharmaceutical agent will be the same for all available package sizes (e.g., 30s, 100s, 1000s) within a given dispensing venue.
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #1 | DoW Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 211ATNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 211ATNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #2 | DoW Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 211ATNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 211ATNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #3 | DoW Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 211ATNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 211ATNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #4 | DoW Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 211ATNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 211ATNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #5 | DoW Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 211ATNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 211ATNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #6 | DoW Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 211ATNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 211ATNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #7 | DoW Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 211ATNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 211ATNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #8 | DoW Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 211ATNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 211ATNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #9 | DoW Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 211ATNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 211ATNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #10 | DoW Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 211ATNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 211ATNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
&"-,Italic"Use or disclosure of data contained on this sheet is subject to the restriction on the title page of this quote.
ADP (non-FAMP Discount)
| UF ADP Appendix for the November 2026 DoW P&T Meeting | |||
| DoW Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | November 4-5, 2026 |
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 |
| Formulary Notes | |||
| Class Note(s): Prior Authorization (PA) may apply and allows for a step that includes any/all generic agents for all new and current users. Agents where no brand currently exists may be considered for tier designation. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend as Completely Excluded from the TRICARE pharmacy benefit program. |
Step Therapy Addendum: Agents with RFQ not submitted or selected may be designated non-step preferred (after-step).
Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.
* Total Calculated Refund Per FCP is calculated as: ((non-FAMP-FCP)+(non-FAMP*Y%)) = Total Calculated Refund **Based on the most recent annual non-FAMP (reported to the Department of Veterans Affairs) from which the current annual Federal Ceiling Price (FCP) calculated ceiling is derived. The current annual FCP and the annual non-FAMP from which it is derived will be applicable to all prescriptions filled during a calendar year. The quoted additional refund percentage will remain static during the life of the agreement but the most recent annual non-FAMP, and thus the calculated refund, may change each calendar year.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DoW Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 211ATNAG1T21M | Tier 2 | 1 or more | |
| 211ATNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DoW Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 211ATNAG1T21M | Tier 2 | 1 or more | |
| 211ATNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DoW Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 211ATNAG1T21M | Tier 2 | 1 or more | |
| 211ATNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DoW Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 211ATNAG1T21M | Tier 2 | 1 or more | |
| 211ATNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote | ||||
| Additional Discount Program Appendix – Newly Approved Drug |
| #5 | DoW Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 211ATNAG1T21M | Tier 2 | 1 or more | |
| 211ATNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DoW Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 211ATNAG1T21M | Tier 2 | 1 or more | |
| 211ATNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DoW Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 211ATNAG1T21M | Tier 2 | 1 or more | |
| 211ATNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DoW Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 211ATNAG1T21M | Tier 2 | 1 or more | |
| 211ATNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DoW Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 211ATNAG1T21M | Tier 2 | 1 or more | |
| 211ATNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote | ||||
| Additional Discount Program Appendix – Newly Approved Drug |
| #10 | DoW Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 211ATNAG1T21M | Tier 2 | 1 or more | |
| 211ATNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
&"-,Italic"Use or disclosure of data contained on this sheet is subject to the restriction on the title page of this quote.
ADP (WAC Discount)
| UF ADP Appendix for the November 2026 DoW P&T Meeting | |||
| DoW Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | November 4-5, 2026 |
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 |
| Formulary Notes | |||
| Class Note(s): Prior Authorization (PA) may apply and allows for a step that includes any/all generic agents for all new and current users. Agents where no brand currently exists may be considered for tier designation. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend as Completely Excluded from the TRICARE pharmacy benefit program. |
Step Therapy Addendum: Agents with RFQ not submitted or selected may be designated non-step preferred (after-step).
Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.
The Wholesale Acquisition Cost (WAC) is obtained from First Databank via daily price updates; it is maintained at the dispensing unit level to five (5) decimal places. If the WAC changes during a calendar quarter, an average WAC will be calculated on a daily weighted basis (per unit only).
WAC is ONLY used for products that do not have a FCP, such as diabetic supplies (i.e., test strips), and can also be applied to covered drugs.
*The quoted WAC Discount percentage will remain static during the life of the agreement.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DoW Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 211ATNAG1T21M | Tier 2 | 1 or more | |
| 211ATNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DoW Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 211ATNAG1T21M | Tier 2 | 1 or more | |
| 211ATNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DoW Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 211ATNAG1T21M | Tier 2 | 1 or more | |
| 211ATNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DoW Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 211ATNAG1T21M | Tier 2 | 1 or more | |
| 211ATNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #5 | DoW Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 211ATNAG1T21M | Tier 2 | 1 or more | |
| 211ATNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DoW Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 211ATNAG1T21M | Tier 2 | 1 or more | |
| 211ATNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DoW Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 211ATNAG1T21M | Tier 2 | 1 or more | |
| 211ATNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DoW Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 211ATNAG1T21M | Tier 2 | 1 or more | |
| 211ATNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DoW Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 211ATNAG1T21M | Tier 2 | 1 or more | |
| 211ATNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #10 | DoW Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 211ATNAG1T21M | Tier 2 | 1 or more | |
| 211ATNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
&"-,Italic"Use or disclosure of data contained on this sheet is subject to the restriction on the title page of this quote.
File details come from the government source that posted it. Updated .